SCHEMBL20049908

SCHEMBL20049908

C=C(C)Nc1ncc(-c2ccc(Cl)cc2)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
CHRNA7 P36544 3/20 0.39
RAB9A P51151 2/20 0.39
SCN10A Q9Y5Y9 1/20 0.39
MAP4K4 O95819 3/20 0.38
NPC1 O15118 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
EGLN1 Q9GZT9 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP2D6 P10635 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
EGLN3 Q9H6Z9 1/20 0.36
EPHB4 P54760 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25588074 0.88 CHRNA7 (0.38) CYP1A2CYP2C19CHRNA7RAB9AMAP4K4
SCHEMBL20049775 0.85 NPC1 (0.42) CHRNA7RAB9ASCN10ANPC1GRIN1
SCHEMBL20049803 0.85 CHRNA7 (0.47) CHRNA7RAB9ANPC1SMN1; SMN2GRIN1
SCHEMBL20049886 0.85 PSMB5 (0.42) RAB9AMAP4K4NPC1HTT
SCHEMBL20049984 0.85 ESR2 (0.47) RAB9AMAP4K4NPC1SMN1; SMN2GRIN1
SCHEMBL25584752 0.84 GRIN2B (0.43) CHRNA7GRIN1GRIN2B
SCHEMBL20049991 0.83 PDGFRB (0.40) CHRNA7NPC1GRIN1GRIN2B
SCHEMBL20050098 0.83 CHRNA7 (0.42) CHRNA7RAB9ANPC1SMN1; SMN2EGLN1
SCHEMBL25588581 0.83 EPHB4 (0.42) RAB9ANPC1SMN1; SMN2EPHB4TEK
SCHEMBL25588429 0.80 GRIN1 (0.35) MAP4K4NPC1GRIN1GRIN2BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018067786-A1 SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-04-12 WO disclosed